National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

racemic XK469
The racemic form of a synthetic quinoxaline phenoxypropionic acid derivative with antineoplastic properties. XK469R selectively inhibits topoisomerase II by stabilizing the enzyme-DNA intermediates in which topoisomerase subunits are covalently linked to DNA through 5-phosphotyrosyl linkages, thereby interfering with DNA repair and replication, RNA and protein synthesis. This agent possesses unusual solid tumor selectivity and activity against multidrug-resistant cancer cells. XK469R is more water soluble and active than the pure isomers, R(+)XK469 and S(-)XK469. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)




Previous:Qvar, R(+)XK469, R-(-)-gossypol acetic acid, R-CHOP regimen, R-flurbiprofen
Next:RadiaPlex Rx Gel, Raf kinase inhibitor XL281, raloxifene, raltitrexed, ramelteon

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov